ABCG2 and chronic myelogenous leukemia, BCR-ABL1 positive: However, different from the ABCG2 inhibitor, the ABCB1 inhibitor was able to restore imatinib sensitivity, indicating that only ABCB1 is essential for the development of acquired resistance in CML.